The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial-Reference-Cited by-同舟云学术

The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial

Published:2008-12-15 Issue:11 Volume:68 Page:1708-1714
ISSN:0003-4967
Container-title:Annals of the Rheumatic Diseases
language:en
Short-container-title:Annals of the Rheumatic Diseases

Author:

Schiff M,Pritchard C,Huffstutter J E,Rodriguez-Valverde V,Durez P,Zhou X,Li T,Bahrt K,Kelly S,Le Bars M,Genovese M C

Publisher

BMJ

Subject

General Biochemistry, Genetics and Molecular Biology,Immunology,Immunology and Allergy,Rheumatology

Cited by 132 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Burden of non-serious infections during biological use for rheumatoid arthritis;PLOS ONE;2024-02-20

2. Malignancy outcomes in patients with rheumatoid arthritis treated with abatacept and other disease-modifying antirheumatic drugs: Results from a 10-year international post-marketing study;Seminars in Arthritis and Rheumatism;2024-02

3. Abatacept and non-melanoma skin cancer in patients with rheumatoid arthritis: a comprehensive evaluation of randomised controlled trials and observational studies;Annals of the Rheumatic Diseases;2023-11-06

4. Long Washout Periods Between Biologics for Inflammatory Bowel Disease Clinical Trials Are Unnecessary: A Canadian Retrospective Cohort Study;American Journal of Gastroenterology;2023-07-06

5. Safety outcomes in patients with rheumatoid arthritis treated with abatacept: results from a multinational surveillance study across seven European registries;Arthritis Research & Therapy;2023-06-12